171 related articles for article (PubMed ID: 10187653)
1. The new pharmaceutical policy in Italy.
Fattore G; Jommi C
Health Policy; 1998 Oct; 46(1):21-41. PubMed ID: 10187653
[TBL] [Abstract][Full Text] [Related]
2. The last decade of Italian pharmaceutical policy: instability or consolidation?
Fattore G; Jommi C
Pharmacoeconomics; 2008; 26(1):5-15. PubMed ID: 18088155
[TBL] [Abstract][Full Text] [Related]
3. Pharmaceutical policy in Italy: towards a structural change?
Ghislandi S; Krulichova I; Garattini L
Health Policy; 2005 Apr; 72(1):53-63. PubMed ID: 15760698
[TBL] [Abstract][Full Text] [Related]
4. European healthcare policies for controlling drug expenditure.
Ess SM; Schneeweiss S; Szucs TD
Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
[TBL] [Abstract][Full Text] [Related]
5. The UK pharmaceutical market. An overview.
Towse A
Pharmacoeconomics; 1996; 10 Suppl 2():14-25. PubMed ID: 10163432
[TBL] [Abstract][Full Text] [Related]
6. The management of the cost and utilisation of pharmaceuticals in the United Kingdom.
Burstall ML
Health Policy; 1997 Sep; 41 Suppl():S27-43. PubMed ID: 10174472
[TBL] [Abstract][Full Text] [Related]
7. Reforms in the Greek pharmaceutical market during the financial crisis.
Vandoros S; Stargardt T
Health Policy; 2013 Jan; 109(1):1-6. PubMed ID: 22959163
[TBL] [Abstract][Full Text] [Related]
8. Pharmaceutical expenditure in Spain: cost and control.
Lopez Bastida J; Mossialos E
Int J Health Serv; 2000; 30(3):597-616. PubMed ID: 11109184
[TBL] [Abstract][Full Text] [Related]
9. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
Davidova J; Praznovcova L; Lundborg CS
Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical cost containment and innovation in the United States.
Kane NM
Health Policy; 1997 Sep; 41 Suppl():S71-89. PubMed ID: 10174475
[TBL] [Abstract][Full Text] [Related]
11. Current national initiatives about drug policies and cost control in Europe: the Italy example.
Rocchi F; Addis A; Martini N;
J Ambul Care Manage; 2004; 27(2):127-31. PubMed ID: 15069990
[TBL] [Abstract][Full Text] [Related]
12. Pharmaceutical expenditure in Sweden.
Henriksson F; Hjortsberg C; Rehnberg C
Health Policy; 1999 May; 47(2):125-44. PubMed ID: 10538288
[TBL] [Abstract][Full Text] [Related]
13. The impact of repeated cost containment policies on pharmaceutical expenditure: experience in Spain.
Moreno-Torres I; Puig-Junoy J; Raya JM
Eur J Health Econ; 2011 Dec; 12(6):563-73. PubMed ID: 20809092
[TBL] [Abstract][Full Text] [Related]
14. Drug cost containment policies in Italy: are they really effective in the long-run? The case of minimum reference price.
Atella V
Health Policy; 2000 Jan; 50(3):197-218. PubMed ID: 10827308
[TBL] [Abstract][Full Text] [Related]
15. Clarifying the scope of Italian NHS coverage. Is it feasible? Is it desirable?
Fattore G
Health Policy; 1999 Dec; 50(1-2):123-42. PubMed ID: 10827304
[TBL] [Abstract][Full Text] [Related]
16. The drug budget silo mentality: the French case.
Le Pen C
Value Health; 2003; 6 Suppl 1():S10-9. PubMed ID: 12846922
[TBL] [Abstract][Full Text] [Related]
17. Pricing and reimbursement of pharmaceuticals in Italy.
Folino-Gallo P; Montilla S; Bruzzone M; Martini N
Eur J Health Econ; 2008 Aug; 9(3):305-10. PubMed ID: 18566845
[TBL] [Abstract][Full Text] [Related]
18. [Assessment of the pharmaceutical expenditure in Hungary].
Inotai A; Merész G; Kaló Z
Acta Pharm Hung; 2010; 80(4):162-72. PubMed ID: 21404477
[TBL] [Abstract][Full Text] [Related]
19. Cost and utilisation of pharmaceuticals in Sweden.
Ljungkvist MO; Andersson D; Gunnarsson B
Health Policy; 1997 Sep; 41 Suppl():S55-69. PubMed ID: 10174474
[TBL] [Abstract][Full Text] [Related]
20. Management of cost and utilization of pharmaceuticals in Germany.
von der Schulenburg JM
Health Policy; 1997 Sep; 41 Suppl():S45-53. PubMed ID: 10174473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
